Alpha memo: Resveratrol - exercise interaction in older men

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Add explicit prose citations to the three additional source-bundle entries (W1541777328, W2001808266, W2078984172) and summarize how they corroborate the narrow-signal reading versus the original 'blunts most effects' framing.
2. Recalibrate the 'Why this is surprising' framing to acknowledge that the reinterpretation was published contemporaneously with the original paper and that the memo is an evidence-map consolidation, not a novel reanalysis.
3. Tighten the receipt-2 description to match the letter's actual variable counts and to note that the 2014 Letter and 2013 reply/rejoinder further constrain the strength of the original 'mainly negative' claim.
4. Confirm in the caveats that the memo's bounded conclusion applies only to ~250 mg/day trans-resveratrol in healthy ~65-year-old men during 8 weeks of high-intensity training, and explicitly note that no human replication or dose-response trial is cited.

Minor issues

• The memo cites only Receipt 1 and Receipt 2 in its narrative but the source bundle contains three additional directly relevant exchanges (the 2014 'friend or foe?' Letter, the Gliemann reply, and the 'Food for thought' commentary). These strengthen the bounded reinterpretation signal and should be integrated into the Evidence Landscape and caveats.
• The 'Why this is surprising' section overstates the novelty by implying this reinterpretation is new; the same reanalysis was already published as a Letter to the Editor in the same journal in 2013 and extended in 2014. The memo should frame this as consolidating/restating an existing critical re-read rather than discovering it.
• Receipt 2 description states 'exercise improved 12 and did not change the remainder' but the letter actually reports exercise improved 12, did not influence 18, and the remainder varied; this nuance should be preserved to avoid a new overclaim.

Reviewer note

This alpha memo isolates a narrow, source-grounded signal: the Gliemann et al. 2013 finding that 250 mg/day trans-resveratrol blunted some exercise-induced cardiovascular adaptations in ~65-year-old men was framed too strongly in the original title/abstract, and a published Letter to the Editor in the same journal demonstrated that of ~45 variables examined only a small subset showed attenuation. The claim is bounded to one dose, one population, one training protocol, and is appropriately hedged. The source bundle is strong: five directly relevant primary items, all from J Physiol 2013–2014, with abstracts that confirm the reinterpretation argument. The memo's main weakness is selective citation within the narrative — it foregrounds only the original paper and the Smoliga & Blanchard letter while the bundle also contains the 2014 'friend or foe?' Letter, the Gliemann reply, and a 'Food for thought' commentary that all bear on the bounded signal and should be explicitly cited. There is also a mild novelty overclaim: the reinterpretation was already public in 2013, so the memo should frame itself as consolidating an existing critical re-read rather than discovering one. Claim-evidence alignment is otherwise good: the memo stays within the cited evidence, uses appropriate hedging ('apparent', 'may be'), and provides concrete falsifiers (multi-dose, longer duration, pre-specified CV endpoints). Limitations are specific and material. Gaps are actionable (decisive RCT design sketched). No structural or methodological defects; fixable with bounded edits to broaden citation integration and temper the novelty framing.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis